CELLECTIS LONG TERM BUY

Hi Guys

Following my ideas redarding #cellectis. A promising french biotech company that already celebrates hugh success with "their" ucart19 against leukemia. Check out my thoughts and join the conversatioin.


TA:

- Double bottom which is normally an indicator for a reversal.
- higher high and higher low
- Oversold Stoch RSI (4hr)
- Rising MACD


Fundamentals:

- CASH POSITION OF $452M AS OF DECEMBER 31, 2018 COMPARED TO $297M AS OF DECEMBER 31, 2017

- CELLECTIS, THROUGH ITS NEW SUBSIDIARY CELLECTIS BIOLOGICS, INC., ENTERED INTO A LEASE AGREEMENT TO BUILD A MANUFACTURING FACILITY IN NORTH CAROLINA, ADVANCING COMMERCIALIZATION CAPABILITIES FOR ITS UCART PORTFOLIO

- UCART123 IN PHASE 1 DOSE ESCALATION CLINICAL TRIAL ONGOING FOR AML

- UCART22 RECEIVED FDA AND IRB APPROVALS FOR PHASE 1 DOSE ESCALATION CLINICAL TRIAL IN B-ALL PATIENTS

- UCART19 ASH ABSTRACT BY PARTNERS SERVIER AND ALLOGENE SHOWED CONTINUED PROGRESS OF FIRST CLINICAL ALLOGENEIC CAR T-CELL PROGRAM FOR ALL ADULT AND PEDIATRIC PATIENTS. MILESTONES PAYMENT CONTRACT WITH PFIZER AND SERVIER UPCOMING

CHECK OUT ALSO THIS AMAZING STORY. WE'RE ABOUT TO CHANCE THE FUTURE BUT ITS A LONG WAY TO GO

google: layla cellectis